Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy.

ABSTRACT:

Background and purpose

CD19-targeting chimeric antigen receptor T-cell (CART) therapy is a promising treatment for relapsed/refractory non-Hodgkin lymphoma, but most patients experience post-CART progression. We describe our institutional experience of salvage radiotherapy (SRT) in this setting.

Materials and methods

Of 94 patients who received CART therapy from 2018 to 2020, 21 received SRT for post-CART progression. Patients were divided into two groups: locoregional disease (n = 9 [43 %], all disease encompassable within an RT field) and advanced disease (n = 12 [57 %]). Patterns of failure, progression-free survival (PFS), overall survival (OS), and toxicity were assessed.

Results

Median time from CART infusion to SRT was 4.0 months (range, 0.6-11.5 months). In th

SUBMITTER: Yegya-Raman N 

PROVIDER: S-EPMC9883177 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature